• 1
    Caldera H, Giralt S. Stem cell transplantation for multiple myeloma: current status and future directions. Curr Hematol Rep. 2004; 3: 249256.
  • 2
    Attal M, Harousseau JL, Stoppa AM, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med. 1996; 335: 9197.
  • 3
    Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 18751883.
  • 4
    Fassas A, Tricot G. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol. 2001; 38: 231242.
  • 5
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98: 492494.
  • 6
    Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol. 2001; 38: 250259.
  • 7
    Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 30633067.
  • 8
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 26092617.
  • 9
    Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2004; 125: 470476.
  • 10
    Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant. 1998; 21: 887892.
  • 11
    Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002; 30: 873878.
  • 12
    Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma: European Group for Bone Marrow Transplantation. N Engl J Med. 1991; 325: 12671273.
  • 13
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000; 18: 30313037.
  • 14
    Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995; 13: 13121322.
  • 15
    Anagnastopoulos A, Aleman A, Giralt S. Nonmyeloablative reduced-intensity transplantation in multiple myeloma. Semin Oncol. 2004; 31: 3336.
  • 16
    Russell N, Bessell E, Stainer C, et al. Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning. Acta Oncol. 2000; 39: 837841.
  • 17
    Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002; 20: 12951303.
  • 18
    Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003; 102: 34473454.
  • 19
    Chronic Leukaemia-Myeloma Task Force. National Cancer Institute: proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep. 1973; 4: 145158.
  • 20
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haemopoetic stem cell transplantation. Br J Haematol. 1998; 102: 11151123.
  • 21
    Shimoni A, Smith TL, Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001: 821828.
  • 22
    Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64: 15461558.
  • 23
    Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002; 117: 297305.
  • 24
    Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002; 99: 31633168.